Caplacizumab
(Unterschied zwischen Versionen)
(Die Seite wurde neu angelegt: „Caplacizumab is a therapeutic monoclonam antibody which interferes with bindung of platelets to extralong vWF multimers. It is first-line acute treatment optio…“) |
K |
||
| Zeile 1: | Zeile 1: | ||
| − | Caplacizumab is a therapeutic | + | Caplacizumab is a therapeutic monoclonal antibody which interferes with binding of platelets to extralong vWF multimers. It is first-line acute treatment option of TTP thrombotic thrombocytopenic purpura. I heard a talk at dgfn2020 and decided to aks the open question, might it be useful for covid19. 3 min answer :)))) |
Nothing at pubmed, some at pmc by full-text cooccurence of phrases, e.g. | Nothing at pubmed, some at pmc by full-text cooccurence of phrases, e.g. | ||
{{ttp|p=32454092|t=2020. Microvascular thrombosis: experimental and clinical implications |pdf=|usr=}} | {{ttp|p=32454092|t=2020. Microvascular thrombosis: experimental and clinical implications |pdf=|usr=}} | ||
Version vom 3. Oktober 2020, 20:15 Uhr
Caplacizumab is a therapeutic monoclonal antibody which interferes with binding of platelets to extralong vWF multimers. It is first-line acute treatment option of TTP thrombotic thrombocytopenic purpura. I heard a talk at dgfn2020 and decided to aks the open question, might it be useful for covid19. 3 min answer :))))
Nothing at pubmed, some at pmc by full-text cooccurence of phrases, e.g.
| 32454092 2020. Microvascular thrombosis: experimental and clinical implications |
